Intra Cellular Therapies reported $50.42M in Current Liabilities for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Acadia Pharmaceuticals ACAD:US $ 95.33M 14.04M
Adamas Pharmaceuticals ADMS:US 21.82M 7.35M
ALKERMES ALKS:US $ 383.44M 17.6M
Aptinyx Inc APTX:US $ 3.38M 496K
Arena Pharmaceuticals ARNA:US $ 64.84M 17.33M
Biogen BIIB:US $ 4211.6M 864.4M
Bristol Myers Squibb BMY:US $ 18991M 1661M
Cytokinetics CYTK:US $ 61.77M 25.84M
Esperion Therapeutics ESPR:US $ 82.64M 15.25M
Gilead Sciences GILD:US $ 10214M 509M
Gw Pharmaceuticals GWPH:US $ 160.25M 0.44M
Halozyme Therapeutics HALO:US $ 114.25M 6.83M
Intra Cellular Therapies ITCI:US $ 50.42M 10.72M
JAZZ PHA JAZZ:US $ 880.59M 128.5M
Marinus Pharmaceuticals MRNS:US $ 16.69M 0.57M
Minerva Neurosciences NERV:US $ 4.44M 1.08M
Nektar Therapeutics NKTR:US $ 131.02M 7.39M
Neurocrine Biosciences NBIX:US $ 212.9M 22.9M
Prothena PRTA:US 52.9M 29.44M
Redhill Biopharma RDHL:US $ 79.17M 12.54M
Supernus Pharmaceuticals SUPN:US $ 283.45M 42.64M
United Therapeutics UTHR:US $ 311.4M 9M
Vanda Pharmaceuticals VNDA:US $ 71.99M 10.2M
Zogenix ZGNX:US $ 69.34M 10.81M